Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
N Engl J Med
    October 2024
  1. SJOHOLM A, Mahma H
    Glycogenic Hepatopathy.
    N Engl J Med. 2024;391:1528.
    >> Share

  2. MEI Z, Pu J, Shao Z
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461-1462.
    >> Share

  3. POLYZOS SA
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461.
    >> Share

    September 2024
  4. COHEN PA, Broad Leib EM
    Ingesting Risk - The FDA and New Food Ingredients.
    N Engl J Med. 2024;391:875-877.
    >> Share

    August 2024
  5. HERNANDEZ PEREZ JM
    Alpha(1)-Antitrypsin Deficiency.
    N Engl J Med. 2024;391:e16.
    >> Share

    July 2024
  6. KANWAL F
    Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2024;391:371-372.
    >> Share

  7. SANYAL AJ, Bedossa P, Fraessdorf M, Neff GW, et al
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
    N Engl J Med. 2024;391:311-319.
    >> Share

  8. SCHUBACH A, Carr RM, Abdelmalek MF
    Hepatologist Consultation in Low-Risk MASLD.
    N Engl J Med. 2024;391:373-375.
    >> Share

    June 2024
  9. GANAPATHI L, Cochran RL, Robbins GK, Barmettler S, et al
    Case 20-2024: A 73-Year-Old Man with Recurrent Fever and Liver Lesions.
    N Engl J Med. 2024;390:2309-2319.
    >> Share

  10. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
    >> Share

    May 2024
  11. KOWDLEY KV, Levy C, Jones D
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1935-1936.
    >> Share

  12. HIRSCHFIELD GM, Kremer AE, Levy C
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1934-1935.
    >> Share

  13. IJICHI H
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1934.
    >> Share

  14. AREVALO-CANAS C, Arevalo-Serrano J
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1933-1934.
    >> Share

  15. NAJEM M, Dong E
    Esophageal Varices, White-Nipple Sign, and Portal Hypertensive Gastropathy.
    N Engl J Med. 2024;390:e47.
    >> Share

  16. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    >> Share

  17. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    >> Share

    February 2024
  18. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    >> Share

  19. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    >> Share

  20. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    >> Share

  21. CUSI K
    Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
    N Engl J Med. 2024;390:559-561.
    >> Share

  22. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    >> Share

    December 2023
  23. CAI S, Kuang M
    Clonorchis sinensis Liver Flukes.
    N Engl J Med. 2023;389:e57.
    >> Share

  24. LOOMBA R, Mansbach H, Margalit M
    Randomized Trial of Pegozafermin in NASH. Reply.
    N Engl J Med. 2023;389:2210.
    >> Share

  25. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    >> Share

    November 2023
  26. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    >> Share

  27. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    >> Share

    September 2023
  28. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    >> Share

  29. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    >> Share

  30. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    >> Share

    August 2023
  31. VALLA DC, Garcia-Pagan JC
    Primary Budd-Chiari Syndrome. Reply.
    N Engl J Med. 2023;389:10.
    >> Share

  32. BORSANI O, Pietra D, Rumi E
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;389:10.
    >> Share

    July 2023
  33. DAUVILLIERS Y, Mignot E, Del Rio Villegas R, Du Y, et al
    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    N Engl J Med. 2023;389:309-321.
    >> Share

    June 2023
  34. BALWANI M, Desnick RJ, Belongie K
    Dersimelagon in Erythropoietic Protoporphyrias. Reply.
    N Engl J Med. 2023;388:2492-2493.
    >> Share

  35. BARMAN-AKSOZEN J, Langendonk JG
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2492.
    >> Share

  36. GRANATA F, Dechant C, Falchetto R
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2491-2492.
    >> Share

    April 2023
  37. BALWANI M, Bonkovsky HL, Levy C, Anderson KE, et al
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:1376-1385.
    >> Share

  38. GARCIA-PAGAN JC, Valla DC
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;388:1307-1316.
    >> Share

    February 2023
  39. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    >> Share

  40. BHAN I, Schaefer EA, Bradley WR, Rodriguez-Lopez JM, et al
    Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.
    N Engl J Med. 2023;388:544-554.
    >> Share

  41. JU H, Liu C
    Cerebral Alveolar Echinococcosis.
    N Engl J Med. 2023;388:453.
    >> Share

    January 2023
  42. GOYAL L, Meric-Bernstam F, Hollebecque A, Valle JW, et al
    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2023;388:228-239.
    >> Share

    December 2022
  43. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    >> Share

  44. OLYNYK JK, Ramm GA
    Hemochromatosis.
    N Engl J Med. 2022;387:2159-2170.
    >> Share

    August 2022
  45. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    >> Share

    July 2022
  46. VERWEIJ N, Haas ME, Nielsen JB, Sosina OA, et al
    Germline Mutations in CIDEB and Protection against Liver Disease.
    N Engl J Med. 2022;387:332-344.
    >> Share

    January 2022
  47. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    >> Share

  48. SANYAL AJ, Van Natta ML, Tonascia J
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:296.
    >> Share

  49. FRANCQUE SM, Bedossa P, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:295-296.
    >> Share

  50. MIR BA, Majeed T, Chauhan A
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:295.
    >> Share

  51. XIA ML, Wang H
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294-295.
    >> Share

  52. HORN P, Newsome PN
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294.
    >> Share

    December 2021
  53. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    >> Share

    November 2021
  54. CHAPMAN MM, Muse VV, Mojica JE, Anahtar MN, et al
    Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia.
    N Engl J Med. 2021;385:1995-2001.
    >> Share

    October 2021
  55. GARCIA-TSAO G
    Nonalcoholic Steatohepatitis - Opportunities and Challenges.
    N Engl J Med. 2021;385:1615-1617.
    >> Share

  56. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    >> Share

  57. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    >> Share

    September 2021
  58. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    >> Share

  59. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    >> Share

  60. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    >> Share

    August 2021
  61. ZOU Q, Li Y
    Hypervirulent Klebsiella pneumoniae.
    N Engl J Med. 2021;385:833.
    >> Share

  62. FREDRICK TW, Neto MBB, Johnsrud DO, Camilleri M, et al
    Turning Purple with Pain.
    N Engl J Med. 2021;385:549-554.
    >> Share

    July 2021
  63. KELLEY RK, Greten TF
    Hepatocellular Carcinoma - Origins and Outcomes.
    N Engl J Med. 2021;385:280-282.
    >> Share

  64. BUTTERS CT, Nash M
    Infantile Hepatic Hemangiomas.
    N Engl J Med. 2021;385:e10.
    >> Share

  65. NEWSOME PN, Sejling AS, Sanyal AJ
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
    N Engl J Med. 2021;385:e6.
    >> Share

  66. DA BL, Satapathy SK
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021;385:e6.
    >> Share

    June 2021
  67. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    >> Share

  68. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    >> Share

  69. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    >> Share

  70. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    >> Share

  71. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    >> Share

  72. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    >> Share

    April 2021
  73. COHN A, Nehs M, Chan J, Vaidya A, et al
    Casting a Wide Net.
    N Engl J Med. 2021;384:e50.
    >> Share

  74. MCINNES IB, Anderson JK, Magrey M, Merola JF, et al
    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    N Engl J Med. 2021;384:1227-1239.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016